Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

Published:2019-05-08 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mascarenhas Leo¹²^ORCID,Lyden Elizabeth R.³,Breitfeld Philip P.⁴⁵,Walterhouse David O.⁶,Donaldson Sarah S.⁷,Rodeberg David A.⁸,Parham David M.⁹,Anderson James R.³¹⁰,Meyer William H.¹¹,Hawkins Douglas S.¹²^ORCID

Affiliation:

1. Saban Research Institute, Children's Hospital Los Angeles Los Angeles California

2. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics, Keck School of Medicine University of Southern California Los Angeles California

3. Department of Preventive and Societal Medicine University of Nebraska Omaha Nebraska

4. Duke University Medical Center Durham North Carolina

5. Breitfeld Group, LLC Chapel Hill North Carolina

6. Department of Pediatrics Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine Chicago Illinois

7. Department of Radiation Oncology Stanford University Stanford California

8. Division of Pediatric Surgery, Department of Surgery East Carolina University Greenville North Carolina

9. Department of Pathology, Children's Hospital Los Angeles, Keck School of Medicine University of Southern California Los Angeles California

10. Oncology Merck Research Laboratories North Wales Pennsylvania

11. Department of Pediatrics University of Oklahoma Health Sciences Center Oklahoma City Oklahoma

12. Department of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center University of Washington Seattle Washington

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32122

Reference29 articles.

1. Cancer incidence among children and adolescents in the United States, 2001‐2003;Li J;Pediatrics,2008

2. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft‐Tissue Sarcoma Committee experience and rationale for current COG studies;Malempati S;Pediatr Blood Cancer,2012

3. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group;Pappo AS;J Clin Oncol,1999

4. Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I;Raney RB;Cancer,1983

5. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy;Chisholm JC;J Clin Oncol,2011

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials;Cancer;2024-06-28

2. Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee;Journal of Pediatric Surgery;2023-11

3. 3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine;Phenomics;2023-10-04

4. Pediatric Rhabdomyosarcomas of the Genitourinary Tract;Cancers;2023-05-22

5. Second‐line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR);Pediatric Blood & Cancer;2023-04-17